Showing Results for
- Academic Journals (7)
Search Results
- 7
Academic Journals
- 7
- Search Terms:
- 1From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedCD40, a tumor necrosis factor receptor family member, is an emerging target for cancer therapy being best appreciated as an important regulator of the anti-tumor immune response. In this study, we report the development...
- 2From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedIn this study, we took advantage of the overexpression of human epidermal growth factor receptor 2 (HER-2) in prostate cancers to design lentiviruses with modified envelope proteins that bind antibodies to specific...
- 3From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedImmunotoxin therapy is a promising molecular cancer treatment strategy. Its main advantage is seletive cytotoxicity towards tumor cells and minimal toxicity in normal tissues. However, a short half-life and rapid...
- 4From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedThe ability of oncolytic adenoviruses to replicate in and lyse cancer cells offers a potential therapeutic approach. However, selectivity and efficacy of adenovirus replication need to be improved. In this study, we...
- 5From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedPancreatic adenocarcinoma is an aggressive and highly lethal malignancy. Currently, gemcitabine is commonly used in patients with pancreatic cancer. However, the life expectancy of pancreatic cancer patients remains...
- 6From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedWe examined cytotoxic effects of adenoviruses (Ad) expressing the p53 gene (Ad-p53) in nine human esophageal carcinoma cell lines with respect to the Ad receptor expression and the endogenous p53 gene status....
- 7From: Cancer Gene Therapy. (Vol. 16, Issue 11) Peer-ReviewedThis review considers comparisons of the off-target effects of siRNA to shRNA and their potential impact on the efficacy and toxicity of RNAi based therapeutics. doi:10.1038/cgt.2009.53; published online 28 August 2009...